Fractyl Health (NASDAQ:GUTS) Issues Quarterly Earnings Results

Fractyl Health (NASDAQ:GUTS) posted its quarterly earnings results on Tuesday. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34, Zacks reports.

Here are the key takeaways from Fractyl Health’s conference call:

• Post‑hoc dose‑response analysis shows longer duodenal ablation (>14–16 cm) strongly correlates with weight‑maintenance; in the optimized subgroup Revita patients regained 2.9% vs 9.9% for sham at six months (≈70% reduction in regain).
• The REMAIN‑1 pivotal is fully randomized with >300 participants across 30+ sites, two pre‑specified co‑primary endpoints and >90% power, with topline six‑month randomized data expected in early Q4 2026.
• FDA feedback indicated Revita’s safety profile is consistent with a moderate‑risk de novo classification, and the company plans a de novo submission in late Q4 2026, a faster and more capital‑efficient pathway than a PMA.
• Cash and equivalents of ~$81.5M (plus $4.1M received post‑period) are expected to fund operations into early 2027, and management has closed the ATM and does not plan a capital raise before pivotal data, creating a narrow financing runway if timelines slip.
• The Rejuva smart GLP‑1 program is progressing (CTAs filed in EU/Australia) with potential first‑in‑human dosing and preliminary data in H2 2026; it is being advanced under a disciplined budget and will not compete with Revita for capital.

Fractyl Health Stock Up 16.2%

Shares of Fractyl Health stock opened at $0.50 on Thursday. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03. The business has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.29. The company has a market cap of $68.52 million, a PE ratio of -0.27 and a beta of 1.51.

Hedge Funds Weigh In On Fractyl Health

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in shares of Fractyl Health during the 4th quarter worth approximately $153,000. Susquehanna Portfolio Strategies LLC purchased a new position in Fractyl Health in the fourth quarter valued at approximately $108,000. Quadrature Capital Ltd grew its holdings in Fractyl Health by 2,047.1% during the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after purchasing an additional 277,174 shares during the period. Millennium Management LLC increased its position in Fractyl Health by 356.6% in the fourth quarter. Millennium Management LLC now owns 1,861,418 shares of the company’s stock worth $4,095,000 after buying an additional 1,453,751 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Fractyl Health in the fourth quarter worth $132,000.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GUTS. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Friday, December 19th. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $8.00 to $2.00 in a report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.40.

Key Headlines Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 results and EPS beat — Fractyl reported Q4 EPS of $0.15, topping the consensus loss estimate and surprising investors; management also released a formal press release with the fourth‑quarter and full‑year 2025 results. Fractyl press release
• Positive Sentiment: Clinical/program progress highlighted — Management emphasized Revita program updates in its shareholder materials and investor commentary, which supports long‑term company value if development milestones continue. Revita progress note
• Positive Sentiment: After‑hours jump and elevated volume — News coverage (MSN) notes a ~21% after‑hours move following the release, and intraday volume ran above average, signaling strong short‑term interest and trade activity. MSN after‑hours coverage
• Positive Sentiment: Short‑interest reduction reported earlier in March — Data showed a sizable drop in reported short interest to ~5.8% of float as of March 13, which can reduce downward pressure and support upside on positive news. (Market data entries)
• Neutral Sentiment: Earnings call transcript — The full Q4 2025 earnings call provides detailed commentary on cash runway, costs and strategic priorities; investors will parse guidance and cadence for future milestones. Earnings call transcript
• Neutral Sentiment: Analyst/coverage summaries — Yahoo and other outlets summarized the quarter and noted financial challenges; the tone is mixed—beat this quarter but still operational/financial questions remain. Yahoo summary
• Negative Sentiment: Ongoing financial and volatility risks — Despite the EPS beat, Wall‑Street consensus still models negative EPS for the fiscal year and the stock trades well below its 50‑ and 200‑day averages; liquidity, cash runway and execution on Revita remain key risk factors for the share price.
• Negative Sentiment: Conflicting short‑interest data — Several data feeds show inconsistent/erroneous short‑interest figures (zero/NaN entries), increasing uncertainty about true short positioning and potential for volatile squeezes or covering spikes that can exaggerate moves in either direction.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.